$24^{\text{th}}$  WHO Expert Committee on Selection and Use of Essential Medicines Expert review

A.17	Flomoxef sodium - EMLc	- intraabdominal and upper urinary tract infections – EML and
Draft recomm		<ul> <li>☑ Recommended</li> <li>☑ Not recommended</li> <li>Justification:</li> <li>Useful carbapenem sparing option for ESBL</li> </ul>
Does the proposed medicine address a relevant public health need?		<ul> <li>Yes</li> <li>□ No</li> <li>□ Not applicable</li> <li>Comments:</li> </ul>
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication?  (this may be evidence included in the application, and/or additional evidence identified during the review process)		☐ Yes ☐ No ☐ Not applicable Comments: Older studies but showing good efficacy
safety/harms a proposed med (this may be evapplication, an	e evidence exist for the associated with the licine?  vidence included in the ad/or additional evidence ing the review process)	<ul> <li>Yes</li> <li>No</li> <li>Not applicable</li> <li>Comments:</li> </ul>
	adverse effects of at may require special	☐ Yes  ☑ No ☐ Not applicable Comments:

## $24^{\text{th}}$ WHO Expert Committee on Selection and Use of Essential Medicines Expert review

Are there any special requirements for the safe, effective and appropriate use of the medicines?  (e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)	☐ Yes ☐ No ☐ Not applicable Comments: IV drug that will require inpatient care in many settings Laboratory support Susceptibility testing not widely available
Are there any issues regarding cost, cost- effectiveness, affordability and/or access for the medicine in different settings?	<ul> <li>✓ Yes</li> <li>☐ No</li> <li>☐ Not applicable</li> <li>Comments:</li> <li>Only available in a few jurisdictions, manufacturing capacity not clear, cost particularly in LMICs not clear</li> </ul>
Are there any issues regarding the registration of the medicine by national regulatory authorities?  (e.g. accelerated approval, lack of regulatory approval, off-label indication)	<ul> <li>✓ Yes</li> <li>☐ No</li> <li>☐ Not applicable</li> <li>Comments:</li> <li>Only registered in a few countries</li> </ul>
Is the proposed medicine recommended for use in a current WHO guideline?  (refer to: <a href="https://www.who.int/publications/who-guidelines">https://www.who.int/publications/who-guidelines</a> )	☐ Yes  ☑ No ☐ Not applicable Comments: